Missed Milestone Prompts Galapagos to Slash Value of Inpharmatica Acquisition | GenomeWeb
NEW YORK (GenomeWeb News) — A missed milestone by Inpharmatica has prompted Galapagos to cut around €7 million from the value of its acquisition of the company, Galapagos said today.
 
The company has already issued 613,000 new shares to former Inpharmatica stockholders, which Galapagos had agreed to acquire last December for as much as €19 million ($25.4 million) in stock.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.